IARJSET ISSN (O) 2393-8021, ISSN (P) 2394-1588

International Advanced Research Journal in Science, Engineering and Technology

Impact Factor 8.311 ⁜ Peer-reviewed & Refereed journal ⁜ Vol. 12, Issue 11, November 2025

DOI: 10.17148/IARJSET.2025.121133

Curcumin Hybrids As Antidiabetic Agent

Ghule Pratiksha Sanjay[1], Ghogare Yashashree Santosh[2], Nikita Rajendra Gawade[3], Vrushali Sanjay Dongare[4], Dr. Devilal Jarpula[5]

Authors, Dattakala College of Pharmacy, Swami Chincholi Daund Tal –Daund, Dist-Pune[1-4]

Guide, Dattakala College of Pharmacy, Swami Chincholi Daund Tal –Daund, Dist-Pune[5]

Abstract: Curcumin hybrids combine the pharmacophore of curcumin with other bioactive molecules, such as metals, synthetic drugs, phytoconstituents, peptides, or Nano carriers, resulting in synergistic pharmacological effects and enhanced pharmacokinetic profiles. Recent studies demonstrate that these hybrids exhibit superior enzyme inhibition (α-glucosidase, α-amylase, DPP-4), improved glucose uptake, enhanced insulin sensitivity, and significant antioxidant activity compared to native curcumin. Moreover, many hybrid derivatives show improved stability, metabolic resistance, and controlled-release behavior. This review summarizes the chemistry of curcumin, types of curcumin hybrids, synthesis strategies, and mechanisms of antidiabetic action, pharmacokinetic benefits, and current research limitations. A detailed discussion on future opportunities including advanced hybrid design, Nano-hybrid systems, molecular docking, and clinical translation is also provided. Curcumin hybrids thus represent a highly promising next-generation therapeutic approach for effective and safer diabetes management. Curcumin hybrids produce synergistic pharmacological effects and improved pharmacokinetic profiles by combining the pharmacophore of curcumin with other bioactive molecules, such as metals, synthetic medicines, phytoconstituents, peptides, or Nano carriers. According to recent research, these hybrids outperform natural curcumin in terms of enzyme inhibition (α-glucosidase, α-amylase, DPP-4), glucose absorption, insulin sensitivity, and antioxidant activity. Additionally, a lot of hybrid derivatives exhibit enhanced controlled-release behaviour, metabolic resistance, and stability. The chemistry of curcumin, types of curcumin hybrids, synthesis techniques, mechanisms of antidiabetic action, pharmacokinetic advantages, and present research limits are all summarized in this paper. Future prospects, such as enhanced hybrid design, Nano-hybrid systems, molecular docking, and clinical translation, are also thoroughly discussed. Thus, curcumin hybrids offer a very promising next-generation treatment strategy for managing diabetes in a safer and more effective manner.

Keywords: Curcumin hybrids, Antidiabetic agents, Type 2 diabetes mellitus, α-amylase inhibition, α-glucosidase inhibition, DPP-4 inhibition, Insulin sensitization, β-cell protection, GLUT-4 translocation, Anti-inflammatory activity, Antioxidant mechanisms, Nanotechnology, Nano-hybrids, Metal–curcumin complexes

I. INTRODUCTION

Over 500 million people worldwide suffer from diabetes mellitus, which has quickly emerged as one of the most common health problems in the world. Sulfonylureas, thiazolidinediones, Biguanides, and DPP-4 inhibitors are examples of modern antidiabetic drugs that are effective but frequently cause adverse effects such hypoglycemia, weight gain, hepatic stress, and gastrointestinal problems[1-2].

Finding safer, plant-based medicinal substances with fewer side effects is thus of increasing scientific interest. Curcuma longa yields curcumin, a yellow polyphenolic substance with strong anti-inflammatory, hypoglycemic, and antioxidant properties. However, because of its weak stability, low water solubility, and quick breakdown under physiological circumstances, its therapeutic value is restricted[3-4].

In order to overcome these limitations, scientists have created curcumin hybrids, which combine curcumin's structural core with other bioactive components to improve stability, solubility, and biological activity. These hybrids exhibit greater pharmacological efficacy, especially in diabetes, where they target various pathways such as improving insulin sensitivity, preserving β-cells, and inhibiting enzymes. An extensive overview of curcumin hybridization techniques and their potential as cutting-edge antidiabetic medicines is given in this paper[5-6].

IARJSET ISSN (O) 2393-8021, ISSN (P) 2394-1588

International Advanced Research Journal in Science, Engineering and Technology

Impact Factor 8.311 ⁜ Peer-reviewed & Refereed journal ⁜ Vol. 12, Issue 11, November 2025

DOI: 10.17148/IARJSET.2025.121133

Fig.1: Curcumin

Chemistry of Curcumin:

Diferuloylmethane is the chemical name for curcumin ($C_{21}H_{22}O_4$). It has a reactive β-diketone moiety and two aromatic rings with o-methoxy and p-Hydroxy groups joined by a seven-carbon linker with conjugated double bonds. Its anti-inflammatory and antioxidant qualities are a result of these structural characteristics[7]. Curcumin has strong radical-scavenging properties due to the keto-enol tautomerism of the β-diketone group. However, its quick metabolism and instability at alkaline pH are caused by the same structure. Its solubility, metabolic resistance, and therapeutic efficiency are all greatly enhanced by structural change through hybrid formation[8].



Fig.2: Chemical Structure of Curcumin

Types of Curcumin Hybrids:

- Metal- Curcumin Hybrids: Zn, Mg, Cu, and Fe complexes enhance antioxidant and insulin-sensitizing properties.
- Drug- Curcumin Hybrids: The glucose-lowering effects of curcumin–metformin, curcumin–thiazolidinedione, and curcumin–sulfonylurea hybrids are synergistic.
- Curcumin-resveratrol, curcumin-quercetin, and curcumin-piperine combinations are examples of phytochemical hybrids that improve bioavailability.
- Nano-Hybrids: Liposomes, micelles, nanogels, and nanoparticles enhance controlled release and delivery.
- Peptide/Amino Acid Hybrids: Boost cell permeability, stability, and receptor targeting.
- Polymer-Conjugated Hybrids: PEGylated and chitosan-curcumin hybrids improve circulation time and solubility[9-10].

II. SYNTHESIS METHODS OF CURCUMIN HYBRIDS

1. To improve biological activity- Stability, and pharmacokinetics, curcumin's two phenolic rings, β-diketone moiety, or methoxy groups are strategically modified to create curcumin hybrid compounds. Depending on the target molecular pathways, desired physical qualities, and functional groups, various synthetic techniques are employed:

1. Select Chemistry (Cu(I)-Catalyzed Azide–Alkyne Cycloaddition – CuAAC)[11] -A potent technique for creating triazole-linked curcumin hybrids is click chemistry. In mild circumstances, the reaction proceeds quickly, yielding stable products. Triazole groups boost enzyme inhibition and antidiabetic actions by increasing molecular stiffness, hydrogen bonding potential, and metabolic stability.

IARJSET ISSN (O) 2393-8021, ISSN (P) 2394-1588

International Advanced Research Journal in Science, Engineering and Technology

Impact Factor 8.311 ⁜ Peer-reviewed & Refereed journal ⁜ Vol. 12, Issue 11, November 2025

DOI: 10.17148/IARJSET.2025.121133

2. Coordination of Metal and Ligand-Curcumin is a naturally occurring bidentate chelating agent that forms complexes with iron, zinc, copper, and manganese. Metal-curcumin hybrids improve glucose absorption, insulin-mimetic qualities (particularly with Zn^{2+}), and antioxidant activity. Additionally, these compounds enhance the light stability, solubility, and redox behaviour of curcumin[12].

3. Green Chemistry Methods-Microwave irradiation, ultrasound-assisted synthesis, ionic liquids, biosynthetic pathways, and solvent-free systems are examples of green synthesis techniques. These increase reaction efficiency and reduce chemical waste. Microbial enzymes or plant extracts can catalyse hybrid formation, creating less hazardous and environmentally friendly compounds that can be developed into pharmaceuticals[13].

III. MECHANISM OF ANTIDIABETIC ACTION

Curcumin hybrids exert antidiabetic activity through multiple molecular and cellular mechanisms, making them potential multi-target therapeutic agents:

1. Inhibition of Carbohydrate-Metabolizing Enzymes- Curcumin hybrids strongly inhibit:

- α-amylase- delays starch breakdown
- α-glucosidase- slows glucose absorption
- DPP-4- increases incretin levels (GLP-1), enhancing insulin release. This reduces postprandial hyperglycemia and improves glycemic control.

2. Enhancement of Insulin Secretion and Protection of β-Cells-Hybrids improve pancreatic β-cell function through[15]:

- upregulation of insulin gene expression
- mitochondrial protection
- inhibition of apoptosis via Bcl-2 pathway
- reduction of oxidative stress and cytokine-induced toxicityhis preserves β-cell mass and improves endogenous insulin production[16].

3. Upregulation of GLUT-4 Translocation-Curcumin hybrids increase GLUT-4 expressionand facilitate its translocation from intracellular vesicles to the cell membrane in:

- skeletal muscle
- Adipose tissue. This leads to increased glucose uptake and improved insulin sensitivity[17].

4. Anti-inflammatory Activity- Curcumin hybrids suppress chronic inflammation associated with insulin resistance by inhibiting:

- NF-κB
- TNF-α
- IL-6
- COX-2
- JNK pathways**.** Reduction in inflammation improves insulin signaling[18].

Pharmacokinetic Improvements with Hybrids[19-20]:

Curcumin's poor bioavailability is a major limitation. Hybrid formation significantly improves pharmacokinetic properties:

1. Increased Solubility and Aqueous Dispersion-Chemical modifications and nano-formulation enhance dissolution rate, leading to better absorption.

2. Improved Chemical Stability-Hybrids protect curcumin from:

- light degradation
- oxidation
- hydrolysis

3. Reduced First-Pass Metabolism- Structural modifications prevent rapid conjugation (glucuronidation/sulfation), prolonging systemic circulation.

4. Higher Bioavailability and Extended Half-Life-Hybrids show greater plasma retention due to:

- Enhanced lipophilicity
- Nano-encapsulation
- Enzyme-resistant linkages

5. Better Cellular Penetration-Hybrid molecules can cross biological membranes more efficiently, improving intracellular activity.

6. Enhanced Target Specificity-By attaching pharmacophores, hybrids can selectively target:

- Liver
- Pancreas
- Adipose tissue
- Gut enzymes

IARJSET ISSN (O) 2393-8021, ISSN (P) 2394-1588

International Advanced Research Journal in Science, Engineering and Technology

Impact Factor 8.311 ⁜ Peer-reviewed & Refereed journal ⁜ Vol. 12, Issue 11, November 2025

DOI: 10.17148/IARJSET.2025.121133

7. Controlled or Sustained Release- Nano-hybrids allow slow and controlled release, maintaining therapeutic levels for longer durations.

Limitations[21-23]:

Curcumin hybrids have drawbacks despite their benefits:

1. Expensive and Complicated Synthesis Methods- Catalysts and specialized equipment are needed for advanced synthetic processes like click chemistry and metal complexation.

2. Insufficient Safety and Toxicological Information-Long-term human safety is yet uncertain, and the majority of research is preclinical.

3. Problems with Stability- Certain hybrids deteriorate in humid and hot environments.

4. Inadequate Clinical Research- Commercialization and regulatory approval are hampered by a lack of clinical data.

5. Difficulties in Growing-Low yields and multi-step processes can make industrial-scale synthesis challenging.

6. Regulatory Limitations-Hybrid phytochemicals need a lot of paperwork since they are in a murky regulatory area.

7. Insufficient Standardised Formulations-Reproducibility and therapeutic effectiveness are impacted by variations in purity and composition.

Future Scope of study[24-25]:

- Curcumin hybrids' potential as antidiabetic drugs offers significant prospects for growth in science, medicine, and industry.
- Using AI-driven drug design, such as molecular docking, QSAR modelling, and machine learning techniques, to anticipate highly active hybrid compounds with multi-target activity is one of the most promising approaches.
- These instruments can be used to find structural changes that enhance receptor affinity, stability, and bioavailability.
- Furthermore, curcumin hybrids may be delivered to pancreatic tissues, liver cells, and adipose tissues in a targeted and long-lasting manner using sophisticated nano-hybrid systems such polymeric nanoparticles, lipid-based carriers, and metal-organic frameworks.
- From an industrial standpoint, the future entails creating economical, scalable, and environmentally friendly synthesis methods while guaranteeing product standardisation, repeatability, and regulatory compliance.
- Therapeutic uses can be expanded by investigating other dose forms, including oral, transdermal, injectables, and nano-suspensions.
- In general, the field is working towards the creation of curcumin hybrid therapies that are patient-specific, highly bioavailable, and multi-target, which could revolutionise the treatment of diabetes in the upcoming decades.
- Clinical translation is another significant future direction. Large-scale human trials are necessary to evaluate pharmacokinetics, safety, optimal dose, and long-term effectiveness because the majority of the information presently comes from in-vitro or animal research.
- In order to treat the multifactorial features of diabetes, hybrid molecules can also be coupled with peptides, incretin-based medicines, or gut-microbiota modulators.
- The creation of personalised antidiabetic medication, where the best hybrid derivative for each patient is determined by metabolic traits and genetic profile, is a significant potential field.

IV. CONCLUSION

Curcumin hybrids have the potential to be complete metabolic modulators, as evidenced by their substantial antioxidant action, protection of pancreatic β-cells, enhancement of GLUT-4 translocation, and reduction of hepatic gluconeogenesis. Curcumin hybrids had better glucose-lowering benefits than curcumin alone, according to preclinical research. Nevertheless, despite these benefits, there are still issues with large-scale manufacture, a lack of standardised formulations, and insufficient human studies that impede application into clinical practice.

With notable advantages over native curcumin in terms of stability, bioavailability, and therapeutic efficiency, curcumin hybrids constitute a very promising class of multi-target antidiabetic medicines. These hybrids circumvent conventional drawbacks including poor solubility, fast metabolism, and low systemic absorption by carefully mixing curcumin with pharmacophores, metal complexes, and nano-delivery methods. They are appropriate for treating the intricate pathophysiology of type 2 diabetes because of their many actions, which include inhibition of α-amylase and α-glucosidase, increase of insulin secretion, suppression of inflammatory pathways, and improvement of lipid metabolism. Future studies must give pharmacokinetic optimisation, toxicological assessment, and regulatory compliance top priority if curcumin hybrids are to become widely used antidiabetic treatments. The gap between laboratory results and practical application will be filled with ongoing innovation in targeted drug design, nano-hybrid systems, and green synthesis techniques. To sum up, curcumin hybrids have enormous potential to develop into

DOI: 10.17148/IARJSET.2025.121133

effective, secure, and multipurpose diabetic control tools. They may function as next-generation treatments that can address both glycaemic management and diabetes complications with thorough scientific validation and technical improvement.

REFERENCES

[1]. Aggarwal, B. B., & Sung, B. (2009). Pharmacological basis for the role of curcumin in chronic diseases. *Biochemical Pharmacology*, 78(11), 1390–1406.
[2]. Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin. *Molecular Pharmaceutics*, 4(6), 807–818.
[3]. Basnet, P., & Skalko-Basnet, N. (2011). Curcumin: An anti-inflammatory molecule. *Journal of Pharmacy and Pharmacology*, 63(4), 375–384.
[4]. Bhawana, et al. (2011). Curcumin nanoparticles: Preparation and characterization. *Colloids and Surfaces B*, 82, 105–113.
[5]. Choudhury, H., et al. (2020). Curcumin-loaded nanocarriers for diabetes. *Journal of Drug Delivery Science and Technology*, 57.
[6]. Gupta, S. C., et al. (2013). Multitargeting by curcumin. *Biofactors*, 39, 78–87.
[7]. Hewlings, S., &Kalman, D. (2017). Curcumin: Health benefits. *Foods*, 6(10), 92.
[8]. Hussain, Z., et al. (2021). Curcumin hybrid molecules. *Current Drug Targets*, 22(4), 421–431.
[9]. Jain, A., et al. (2022). Curcumin-based antidiabetics. *Phytotherapy Research*, 36(9), 3688–3703.
[10]. Jayaprakasha, G. K., et al. (2005). Chemistry of curcumin. *Journal of Agricultural and Food Chemistry*, 53, 6938–6946.
[11]. Kharat, M., et al. (2017). Curcumin stability. *Food Chemistry*, 235, 295–302.
[12]. Khan, H., et al. (2019). Curcumin hybrids: Recent progress. *European Journal of Medicinal Chemistry*, 163, 465–477.
[13]. Kocaadam, B., &Sanlier, N. (2017). Curcumin and human health. *Critical Reviews in Food Science and Nutrition*, 57(13), 2889–2895.
[14]. Kumar, A., et al. (2020). Antidiabetic effects of curcumin derivatives. *Journal of Ethnopharmacology*, 250.
[15]. Li, S., et al. (2011). Curcumin pharmacology. *British Journal of Pharmacology*, 166, 1987–2006.
[16]. Liu, W., et al. (2016). Nano-curcumin delivery. *Drug Delivery*, 23(4), 1320–1328.
[17]. Ma, Z., et al. (2019). Curcumin-metal complexes. *Coordination Chemistry Reviews*, 389, 1–20.
[18]. Maheshwari, R. K., et al. (2006). Curcumin anti-inflammatory potential. *Life Sciences*, 78(18), 2081–2087.
[19]. Menon, V., et al. (2021). Curcumin conjugates. *Journal of Molecular Structure*, 1224.
[20]. Meng, B., et al. (2013). Targeted delivery of curcumin. *Fitoterapia*, 84, 84–94.
[21]. Mittal, S., et al. (2014). Curcumin and metabolic disorders. *Nutrition Research Reviews*, 27, 117–127.
[22]. Mohanty, C., & Sahoo, S. K. (2010). Nano-curcumin. *Drug Discovery Today*, 15(15-16), 710–718.
[23]. Prasad, S., et al. (2014). Curcumin and chronic diseases. *Nutrition and Cancer*, 66, 1–8.
[24]. Rahimi, R., &Abdollahi, M. (2016). Herbal antidiabetic agents. *Archives of Medical Science*, 12(3), 578.
[25]. Rathore, B., et al. (2020). Curcumin hybrids in diabetes. *Mini-Reviews in Medicinal Chemistry*, 20, 1474–1490.
[26]. Sharma, R. A., et al. (2005). Curcumin pharmacokinetics. *Clinical Cancer Research*, 11, 7490–7498.
[27]. Shehzad, A., et al. (2011). Curcumin and cancer pathways. *Journal of Cellular and Molecular Medicine*, 15, 657–674.
[28]. Singh, S. (2007). Curcumin stability problems. *AAPS Journal*, 9(3), 417–424.
[29]. Wang, Y., et al. (2018). Curcumin and metabolic modulation. *Pharmacological Research*, 128, 124–132.
[30]. Zhou, H., &Beevers, C. S. (2011). Curcumin mechanisms. *Cancer Research*, 71, 599–605.

